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Abstract
High levels of adherence to antiretroviral therapy (ART) are necessary for achieving and
maintaining optimal virological suppression, as suboptimal adherence leads to therapy fail-
ure and disease progression. It is well known that adherence to ART predicts therapy
response, but it is unclear whether clinical outcomes of ART predict adherence. To examine
the predictive power of current CD4+ T cell count for adherence of HIV-infected individuals
to ART, we performed a cross-sectional analysis of 133 Dutch HIV patients with electroni-
cally measured adherence. In a multivariate analysis adjusting for a number of sociodemo-
graphic and clinical variables, high current CD4+ T cell count (>660 cells/mm3) was most
strongly associated with lower adherence to ART (assessed as a continuous variable) dur-
ing a two-month period immediately following the measurements of variables (P = 0.008).
The twice-per-day (versus once-per-day) dosing regimen was also significantly associated
with lower adherence (P = 0.014). In a second multivariate analysis aimed at determining
the predictors of suboptimal (<100% of the doses taken) adherence, high current CD4+ T
cell count was again the strongest independent predictor of suboptimal adherence to ART
(P = 0.015), and the twice-per-day dosing regimen remained associated with suboptimal
adherence (P = 0.025). The association between suboptimal adherence and virological sup-
pression was significant in patients with high CD4+ T cell counts, but not in patients with low
or intermediate CD4+ T cell counts (P = 0.036 and P = 0.52, respectively; P = 0.047 for com-
parison of the effects of adherence on virological suppression between patients with high
vs. low or intermediate CD4+ T cell counts), suggesting that apart from promoting subopti-
mal adherence, high CD4+ T cell count also strengthens the effect of adherence on virologi-
cal suppression. Therefore, sustained efforts to emphasize continued adherence are
necessary, especially for patients with high CD4+ T cell counts.
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Introduction
High levels of adherence to antiretroviral therapy (ART) are necessary for achieving and main-
taining optimal virological suppression [1,2], as suboptimal adherence leads to therapy failure
and disease progression [3,4]. It is well known that adherence to ART predicts therapy
response [5,6]. However, it is unclear whether the opposite is true, i.e. whether clinical out-
comes of ART (plasma viral load and CD4+ T cell count) predict adherence.
The CD4+ T cell count is an important measure of clinical outcome of therapy, and a good
immunological response is an integral part of success on ART. High CD4+ count, coupled to
undetectable plasma viral load, delivers a reassuring message of success on ART to the patient,
whereas low CD4+ count despite virological suppression may signal that the therapy is not
working as it should. Because the patients’ perceptions of ART influence adherence [7,8],
CD4+ count may therefore be a predictive factor for adherence to therapy. However, it is diffi-
cult to speculate about the exact effect that CD4+ count could have on adherence. For example,
a high CD4+ count, signaling therapy success, may either encourage a patient to be more
adherent, or it may, on the contrary, result in the decreased attention to taking all antiretroviral
drugs each day. In the latter case, timely behavioral intervention is important.
Surprisingly, to date no study has specifically addressed, and very few studies have men-
tioned, the influence of current CD4+ count on adherence. Moreover, studies that did report
such an association provided conflicting results [9,10]. The aim of the current study was to
examine the relationship between current CD4+ count and electronically monitored adherence
to ART, while controlling for a number of sociodemographic and clinical variables, in 133
Dutch patients on suppressive ART.
Methods
We conducted a cross-sectional analysis of 133 Dutch patients visiting the HIV outpatient
clinic of the Academic Medical Center (Amsterdam, the Netherlands) in 2005–2006, who were
participating in a randomized controlled trial investigating the effects of a behavioral interven-
tion to increase adherence. The results of the trial were reported previously [11]. Patients were
eligible if they were older than 18 years, treatment-experienced (>6 months on ART), started
antiretroviral treatment in 1996 or later, and had no uncontrolled psychiatric or drug addiction
problems that would prevent them from being able to comply with the study procedures
(patients with such problems constitute an extremely small part of our patient population: out
of 348 screened patients, 5 and 7 patients were not approached because of severe psychological
and drug addiction problems, respectively). Since the nurses preferred to apply this new inter-
vention initially without the additional challenge of language and/or cultural barriers, the trial
was focused on native Dutch patients (the main patient population in the Netherlands). The
study was approved by the Medical Ethical Committee of the Academic Medical Center, and
all patients provided written informed consent. The study has been conducted in accordance
with the ethical principles in the Declaration of Helsinki.
The time period analyzed in the current study corresponds to a two-month adherence mon-
itoring period between patient inclusion and randomization [11]. Besides measuring adher-
ence, no interventions took place during this period. The subsequent group allocation and
adherence interventions could not influence the results of the present study and are not
reported here. The following sociodemographic and clinical variables were collected at inclu-
sion: age, gender, education level, current employment, ART regimen, dosing regimen, time on
ART, time on ART with undetectable plasma viral load, current CD4+ T cell count, nadir
CD4+ T cell count, and current plasma viral load detectability. Adherence was measured elec-
tronically using MEMS-cap pill bottles (Aardex, Switzerland) during two-month periods
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PLOS ONE | DOI:10.1371/journal.pone.0140791 October 15, 2015 2 / 11
immediately following the assessment of variables. MEMS-cap pill bottles recorded the
moments of bottle opening electronically. Adherence as measured by MEMS was defined as
the percentage of prescribed doses actually taken during the assessment period, and was calcu-
lated by dividing the number of times the pill bottle had been opened by the number of times it
should have been opened, multiplied by 100.
Explanatory power of the sociodemographic and clinical variables was examined both for
adherence as a continuous variable and for<100% adherence versus 100% adherence. This
cutoff was based on fitting receiver operating characteristic (ROC) curve and Fisher’s exact
tests to determine the most clinically significant cutoff value of adherence for virological sup-
pression. Continuous predictors were dichotomized by tertiles to high, intermediate, and low
categories with intermediate category used as a reference category. For the univariate analysis
of adherence as a continuous variable, nonparametric Mann-Whitney tests were used to com-
pare adherence values between different categories of a given predictor, and a generalized linear
model (GeLM) using a rank-transformed dependent variable was fitted for the multivariate
analysis. To analyze the predictive value of variables for suboptimal adherence (<100%), we
used logistic regression (enter method). Fisher’s exact tests were used to determine effects of
CD4+ count on virological suppression and effects of adherence on virological suppression in
different CD4+ count strata. Cochran–Mantel–Haenszel test was used to compare the effects
of adherence on virological suppression between patients with high vs. low or intermediate
CD4+ T cell counts. GeLM, ROC curve analysis, and logistic regression were performed
using IBM SPSS Statistics 22 (available at: http://www.spss.com). Mann-Whitney and Fisher’s
tests were performed using GraphPad Prism 5.01 (available at: http://www.graphpad.com).
Cochran–Mantel–Haenszel test was performed using a spreadsheet available at http://www.
biostathandbook.com/cmh.html. All statistical tests were two-sided. P values of<0.05 were
considered statistically significant.
Results
Patient characteristics are shown in Table 1. Median age was 47.2 years and 91% were males.
At the moment of measurements, patients had been treated with suppressive ART for a median
of 50.6 months (median 41.6 months of continuous plasma viral load suppression) and had a
median CD4+ T cell count of 590 cells/mm3. Median CD4+ T cell count nadir was 150 cells/
mm3. Low-level plasma viral load was detectable (>50 copies/ml) in 7.1% of patients. Adher-
ence was high in this patient cohort: 73.7% of patients demonstrated adherence of>95% and
51.1% of patients were 100% adherent. Only 9.0% of patients demonstrated <80% adherence.
We started with analyzing the factors associated with adherence as a continuous variable. In
the univariate analysis, a twice-per-day dosing regimen, heterosexual transmission route, and
high current CD4+ T cell count (highest tertile:>660 cells/mm3) were significantly associated
with lower adherence (Table 2). In the multivariate analysis, high current CD4+ T cell count
and twice-per-day dosing regimen remained associated with lower adherence (P = 0.008 and
P = 0.014, respectively). High CD4+ T cell count nadir and longer time on therapy with unde-
tectable plasma viral load were associated with higher adherence with borderline significance
(P = 0.034 and P = 0.045, respectively).
Because we sought to determine the predictors of a clinically significant adherence level, we
next established the most clinically significant cutoff value of adherence for prediction of
detectable plasma viral load. To this end, we used the plasma viral load values measured
directly after the adherence assessment period. The proportion of virologically suppressed
patients (plasma viral load<50 copies/ml) was 83.6% in all patients, 66.7% in patients with
<80% adherence, 78.3% in patients with 80–94% adherence, 76.7% in patients with 95–99%
ART Adherence and CD4+ T Cell Count
PLOS ONE | DOI:10.1371/journal.pone.0140791 October 15, 2015 3 / 11
adherence, and 92.1% in patients with 100% adherence (S1 Fig). This suggested that 100%
might be the optimal adherence level in this cohort. Indeed, the ROC curve analysis revealed
that 100% was the most clinically significant cutoff value of adherence for prediction of detect-
able plasma viral load (S1 Table). This was confirmed by direct comparison of different adher-
ence cutoff values (Table 3): 100% was the only cutoff value that could significantly predict
detectable plasma viral load (OR (95% CI) = 3.79 (1.29–11.1), P = 0.016).
Next, we determined the predictors of suboptimal (<100%) adherence to ART. In the uni-
variate analysis, high current CD4+ T cell count (>660 cells/mm3) and a twice-per-day dosing
regimen were significantly associated with suboptimal adherence (Table 4). Both these factors
remained significantly predictive of suboptimal adherence in the multivariate model (OR (95%
CI): 6.21 (1.42–27.0), P = 0.015 and 3.27 (1.16–9.17), P = 0.025, respectively). Therefore, high
current CD4+ T cell count was the strongest independent predictor of suboptimal adherence.
Next, we determined whether the effect of high current CD4+ T cell count on adherence
translates into the effect of high current CD4+ T cell count on virological suppression. Immedi-
ately after the adherence assessment period, plasma viral load was detectable in 8 out of 43
(18.6%) patients with high CD4+ count, compared with 11 out of 79 (13.9%) patients with low
or intermediate CD4+ count. Thus, the overall contribution of high current CD4+ T cell count
Table 1. Characteristics of the patients.
Age, years (n = 133) 47.2 (40.9–54.6)1
Gender (n = 133) Female 9.0 (12/133)
Male 91.0 (121/133)
Transmission route (n = 120) Heterosexual 19.2 (23/120)
Intravenous drug use 0.8 (1/120)
MSM 80.0 (96/120)
Education (n = 128) Low 25.8 (33/128)
Middle 35.9 (46/128)
High 38.3 (49/128)
Currently employed (n = 122) Yes 68.0 (83/122)
No 32.0 (39/122)
Antiretroviral therapy (n = 128) NNRTI-based 60.2 (77/128)
PI-based 28.9 (37/128)
Other2 10.9 (14/128)
Dosing regimen (n = 133) One dose/day 60.2 (80/133)
Two doses/day 39.8 (53/133)
Time on therapy, months (n = 129) 50.6 (19.5–90.5)
Time on therapy with undetectable plasma viral load, months (n = 129) 41.6 (15.8–76.2)
Current CD4+ T cell count, cells/mm3 (n = 127) 590 (380–720)
CD4+ T cell count nadir, cells/mm3 (n = 128) 150 (60–227)
Current plasma viral load (n = 127) >50 copies/ml 7.1 (9/127)
<50 copies/ml 92.9 (118/127)
Adherence to ART, % (n = 133) 100 (94.7–100)
<80% 9.0 (12/133)
80–94% 17.3 (23/133)
95–99% 22.6 (30/133)
100% 51.1 (68/133)
1Data are medians (interquartile ranges) for continuous variables and % (proportions) for discrete variables.
2Triple NRTI (n = 9), PI+NNRTI-based (n = 5).
doi:10.1371/journal.pone.0140791.t001
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to the detectability of plasma viral load was insignificant (OR (95% CI): 1.41 (0.52–3.83),
P = 0.60). Finally, to determine whether the effects of adherence on virological suppression dif-
fered among patients with high versus low or intermediate CD4+ T cell counts, we stratified the
patients based on their CD4+ counts and analyzed the predictive value of suboptimal adherence
for plasma viral load detectability separately in both strata (Table 5). In patients with low or
intermediate CD4+ counts, 17.1% and 11.4% of patients with suboptimal and optimal adher-
ence, respectively, had detectable plasma viral load (P = 0.52). However, in patients with
high CD4+ counts, 28.6% of patients with suboptimal adherence, but no patients with
optimal adherence, had detectable plasma viral load (P = 0.036). The effect of adherence on
virological suppression was stronger in patients with high vs. low or intermediate CD4+ counts
(P = 0.047). Therefore, apart from promoting suboptimal adherence, high CD4+ T cell count
also appeared to boost the effect of adherence on virological suppression.
Table 2. Factors associated with adherence to ART (measured as continuous variable).
Variable Adherence, %1 P Adjusted P
Age (n = 133) <42 years (n = 46) 100 (94.2–100) 0.49 0.27
42–52 years (n = 42) 98.2 (94.4–100)
>52 years (n = 45) 100 (95.6–100) 0.27 0.60
Gender (n = 133) Female (n = 12) 96.4 (88.9–100) 0.14 0.69
Male (n = 121) 100 (95.5–100)
Transmission route Heterosexual (n = 23) 96.5 (88.4–100)
(n = 120) Intravenous drug use (n = 1) 96.9
MSM (n = 96) 100 (96.4–100) 0.033 0.67
Education (n = 128) Low (n = 33) 98.2 (94.2–100) 0.79 0.30
Middle (n = 46) 98.7 (91.3–100)
High (n = 49) 100 (96.9–100) 0.12 0.73
Currently employed Yes (n = 83) 100 (95.5–100)
(n = 122) No (n = 39) 100 (96.5–100) 0.44 0.73
Antiretroviral therapy NNRTI (n = 77) 99.2 (94.7–100)
(n = 128) PI (n = 37) 100 (96.7–100) 0.39 0.44
Other (n = 14) 98.2 (93.3–100) 0.88 0.96
Dosing regimen One dose/day (n = 80) 100 (96.4–100)
(n = 133) Two doses/day (n = 53) 98.2 (92.4–100) 0.036 0.014
Time on <30 months (n = 43) 99.2 (95.5–100) 0.37 0.93
therapy (n = 129) 30–72 months (n = 44) 98.2 (91.9–100)
>72 months (n = 42) 100 (95.7–100) 0.26 0.40
Time on therapy with <24 months (n = 41) 99.2 (95.1–100) 0.49 0.84
undetectable plasma 24–65 months (n = 46) 98.2 (92.6–100)
viral load (n = 129) >65 months (n = 42) 100 (96.0–100) 0.25 0.045
Current CD4+ T cell <450 cells/mm3 (n = 43) 100 (97.3–100) 0.71 0.65
count (n = 127) 450–660 cells/mm3 (n = 39) 100 (96.5–100)
>660 cells/mm3 (n = 45) 97.3 (91.5–100) 0.030 0.008
CD4+ T cell count <100 cells/mm3 (n = 41) 100 (96.5–100) 0.26 0.29
nadir (n = 128) 100–200 cells/mm3 (n = 46) 98.7 (90.6–100)
>200 cells/mm3 (n = 41) 100 (96.4–100) 0.24 0.034
Current plasma viral >50 copies/ml (n = 9) 96.5 (73.2–100) 0.19 0.35
load (n = 127) <50 copies/ml (n = 118) 100 (94.7–100)
1Data are medians (interquartile ranges).
doi:10.1371/journal.pone.0140791.t002
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Discussion
A number of factors associated with suboptimal adherence to ART have been identified previ-
ously, such as younger age, greater pill burden, lower education level, side effects of therapy,
and interference with other activities [2,10,12,13,14]. Patients’ beliefs about ART and percep-
tions of therapy success or failure have also been shown to predict adherence [7,8]. As clinical
outcomes may contribute to patients’ perceptions of therapy and its effects and thus may influ-
ence subsequent behavior [15], CD4+ counts could be expected to influence adherence. Indeed,
in our cohort, patients with high (>660 cells/mm3) current CD4+ counts were, on average, six
times more likely to demonstrate suboptimal adherence as compared to patients with interme-
diate (450–660 cells/mm3) CD4+ T cell counts. Interestingly, patients with intermediate CD4+
counts did not demonstrate higher rates of suboptimal adherence compared to patients with
low (<450 cells/mm3) CD4+ T cell counts. This suggests that the relationship between CD4+
count and adherence is nonlinear and that only patients with relatively high CD4+ counts dem-
onstrate suboptimal adherence. Further studies in larger cohorts are necessary to address these
issues.
To our knowledge, very few studies have previously reported an association between current
CD4+ count on ART and adherence to therapy. One study [9] reported higher rates of subopti-
mal adherence by higher current CD4+ count, whereas another study reported the opposite
effect [10]. However, in these studies adherence was monitored by self-reporting, which is
known to be imprecise and to overestimate adherence [3]. In contrast, adherence was moni-
tored electronically in our study. Electronic monitoring was shown to be more sensitive than
self-reporting for the detection of nonadherence [1]. In addition, half of the patients in the
study by O’Connor et al. [10] received interrupted ART guided by the CD4+ count, whereas
our patients had been on continuous ART for a median of 50.6 months before they entered the
study and did not interrupt therapy throughout the study. It is possible that this can explain
the difference between the effects of current CD4+ T cell count on adherence observed by
O’Connor et al. and our study. Interestingly, Venkatesh et al. reported higher odds of subopti-
mal adherence by higher current CD4+ count and by longer time on ART [9]. They argued that
treatment exhaustion was responsible for the observed effects. In contrast, treatment fatigue
was unlikely to mediate the effect of higher current CD4+ count on adherence observed in our
study, as longer time on ART was not associated with poor adherence. This is in line with the
results of Cambiano et al. who studied long-term trends in adherence to ART in>2,000
Table 3. Comparison of different adherence cutoff values for the prediction of detectable plasma viral load.
Adherence
threshold
All patients
(n = 128)
Patients with pVL1>50 copies/ml
(n = 21)
Patients with pVL<50 copies/ml
(n = 107)
OR (95% CI) P
80% 90.1 (116/128) 81.0 (17/21)2 92.5 (99/107) 2.91 (0.79–
10.8)
0.11
85% 89.1 (114/128) 81.0 (17/21) 90.7 (97/107) 2.28 (0.64–
8.12)
0.25
90% 82.8 (106/128) 81.0 (17/21) 83.2 (89/107) 1.16 (0.35–
3.87)
0.76
95% 72.7 (93/128) 57.1 (12/21) 75.7 (81/107) 2.34 (0.89–
6.17)
0.11
100% 49.2 (63/128) 23.8 (5/21) 54.2 (58/107) 3.79 (1.29–
11.1)
0.016
1pVL, plasma viral load.
2Shown are % (proportions) of patients with adherence higher than or equal to the respective adherence threshold.
doi:10.1371/journal.pone.0140791.t003
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Table 4. Factors associated with suboptimal adherence to ART.
Variable All patients Patients with
100%
Patients with
<100%
OR (95% CI) P Adjusted OR P
(n = 133) adherence
(n = 68)
adherence
(n = 65)
(95% CI)
Age (n = 133) 47.2 (40.9–54.6)1 48.1 (40.5–54.8) 44.9 (41.2–53.8) 0.72
<42 years 34.6 (46/133) 36.8 (25/68) 32.3 (21/65) 0.63 (0.27–1.46) 0.28 0.44 (0.13–1.48) 0.18
42–52 years 31.6 (42/133) 26.5 (18/68) 36.9 (24/65) 1.00 1.00
>52 years 33.8 (45/133) 36.8 (25/68) 30.8 (20/65) 0.60 (0.26–1.40) 0.24 0.95 (0.27–3.34) 0.93
Gender (n = 133) Female 9.0 (12/133) 5.9 (4/68) 12.3 (8/65) 2.25 (0.64–7.87) 0.21 1.31 (0.18–9.43) 0.79
Male 91.0 (121/133) 94.1 (64/68) 87.7 (57/65) 1.00 1.00
Education
(n = 128)
Low 25.8 (33/128) 21.2 (14/66) 30.6 (19/62) 1.24 (0.51–3.06) 0.64 1.82 (0.47–7.14) 0.39
Middle 35.9 (46/128) 33.3 (22/66) 38.7 (24/62) 1.00 1.00
High 38.3 (49/128) 45.5 (30/66) 30.6 (19/62) 0.58 (0.26–1.31) 0.19 0.73 (0.24–2.21) 0.58
Currently
employed
Yes 68.0 (83/122) 65.2 (43/66) 71.4 (40/56) 1.00 1.00
(n = 122) No 32.0 (39/122) 34.8 (23/66) 28.6 (16/56) 0.75 (0.35–1.62) 0.46 0.69 (0.22–2.20) 0.53
Antiretroviral
therapy
NNRTI 60.2 (77/128) 59.4 (38/64) 60.9 (39/64) 1.00 1.00
(n = 128) PI 28.9 (37/128) 31.3 (20/64) 26.6 (17/64) 0.83 (0.38–1.82) 0.64 0.89 (0.29–2.77) 0.84
other 10.9 (14/128) 9.4 (6/64) 12.5 (8/64) 1.30 (0.41–4.10) 0.66 1.56 (0.30–8.20) 0.60
Dosing regimen One dose/day 60.2 (80/133) 70.6 (48/68) 49.2 (32/65) 1.00 1.00
(n = 133) Two doses/day 39.8 (53/133) 29.4 (20/68) 50.8 (33/65) 2.48 (1.21–5.05) 0.013 3.27 (1.16–9.17) 0.025
Transmission
route
Heterosexual 19.2 (23/120) 13.3 (8/60) 25.0 (15/60) 1.00 1.00
(n = 120) IV drug use 0.8 (1/120) 0.0 (0/60) 1.7 (1/60)
MSM 80.0 (96/120) 86.7 (52/60) 73.3 (44/60) 0.45 (0.18–1.16) 0.10 0.87 (0.18–4.13) 0.86
Time on 50.6 (19.5–90.5) 49.1 (19.0–94.9) 54.5 (19.9–83.2) 0.82
therapy (n = 129) <30 months 33.3 (43/129) 32.3 (21/65) 34.4 (22/64) 0.87 (0.38–2.03) 0.75 0.73 (0.10–5.41) 0.75
30–72 months 34.1 (44/129) 30.8 (20/65) 37.5 (24/64) 1.00 1.00
>72 months 32.6 (42/129) 36.9 (24/65) 28.1 (18/64) 0.63 (0.27–1.46) 0.28 1.94 (0.36–10.3) 0.44
Time on therapy
with
41.6 (15.8–76.2) 40.4 (16.3–82.0) 41.7 (15.1–67.3) 0.59
undetectable
plasma
<24 months 31.8 (41/129) 30.8 (20/65) 32.8 (21/64) 0.88 (0.38–2.05) 0.77 2.21 (0.32–15.2) 0.42
viral load
(n = 129)
24–65 months 35.7 (46/129) 32.3 (21/65) 39.1 (25/64) 1.00 1.00
>65 months 32.6 (42/129) 36.9 (24/65) 28.1 (18/64) 0.63 (0.27–1.46) 0.28 0.18 (0.03–1.23) 0.080
Current CD4+ T
cell
590 (380–720) 560 (393–670) 610 (370–730) 0.61
count (n = 127) <450 cells/mm3 33.9 (43/127) 35.9 (23/64) 31.7 (20/63) 1.39 (0.58–3.36) 0.46 0.96 (0.25–3.62) 0.95
450–660 cells/
mm3
30.7 (39/127) 37.5 (24/64) 23.8 (15/63) 1.00 1.00
>660 cells/mm3 35.4 (45/127) 26.6 (17/64) 44.4 (28/63) 2.64 (1.09–6.37) 0.031 6.21 (1.42–27.0) 0.015
CD4+ T cell count 150 (60–227) 150 (60–250) 150 (60–210) 0.89
nadir (n = 128) <100 cells/mm3 32.0 (41/128) 32.3 (21/65) 31.7 (20/63) 0.80 (0.34–1.86) 0.60 0.88 (0.29–2.75) 0.83
100–200 cells/
mm3
35.9 (46/128) 32.3 (21/65) 39.7 (25/63) 1.00 1.00
>200 cells/mm3 32.0 (41/128) 35.4 (23/65) 28.6 (18/63) 0.66 (0.28–1.53) 0.33 0.36 (0.10–1.27) 0.11
Current plasma
viral
>50 copies/ml 7.1 (9/127) 4.7 (3/64) 9.5 (6/63) 2.14 (0.51–8.93) 0.30 1.88 (0.30–11.9) 0.50
(Continued)
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patients and found that adherence does not decrease with time on therapy [16]. However,
another group did report a decrease in adherence with time [17].
Several groups studied an effect of baseline (pre-therapy) CD4+ count on the subsequent
adherence to ART. Some studies reported an association between higher (>200 or>250 cells/
mm3) baseline CD4+ count and lower adherence [18], whereas others could not find such an
effect [2,19]. A recent study found that higher baseline CD4+ count predicted treatment inter-
ruptions but not lower average adherence [19]. In our study, unlike high current CD4+ count,
high nadir CD4+ count (which for most patients coincided with the moment of ART initiation)
was not associated with suboptimal adherence. This might reflect the fact that our patients on
average had been more than 4 years on therapy before the study was initiated and their behav-
ior might therefore have been more dependent on the perception of their current than of their
pre-therapy health status.
Besides the high current CD4+ count, the only variable significantly associated with subopti-
mal adherence in the multivariate analysis was twice-per-day dosing regimen, as compared
with the once-daily regimen, confirming other studies that have reported decreasing adherence
as the number of pills per day increases [10,20,21].
In this cohort, 100% adherence was found to be the only significant cutoff value of adher-
ence for prediction of detectable plasma viral load. Also, levels of virological suppression in
patients with 100% adherence were higher than in other adherence strata, including patients
with 95–99% adherence (S1 Fig). This is in line with an earlier study by Paterson et al. that has
found that patients with adherence of 95% or higher had better virological outcomes than
patients with lower adherence [2]. However, some more recent studies have found that lower
adherence thresholds (sometimes as low as 55–70%, depending on the ART regimen) might be
more clinically significant, as rates of virological rebound in plasma were not found to be
higher in patients with modest nonadherence [22,23]. The much more strict adherence
Table 4. (Continued)
Variable All patients Patients with
100%
Patients with
<100%
OR (95% CI) P Adjusted OR P
(n = 133) adherence
(n = 68)
adherence
(n = 65)
(95% CI)
load (n = 127) <50 copies/ml 92.9 (118/127) 95.3 (61/64) 90.5 (57/63) 1.00 1.00
1Data are % (proportion) of patients or median value (interquartile range).
doi:10.1371/journal.pone.0140791.t004
Table 5. Effects of adherence on virological suppression among patients with high versus low or intermediate CD4+ T cell counts.
Adherence <100% Adherence 100% P
CD4+ T cell count pVL1 <50 copies/ml 292 39 0.52
660 cells/mm3 pVL >50 copies/ml 6 5
CD4+ T cell count pVL <50 copies/ml 20 15 0.036
>660 cells/mm3 pVL >50 copies/ml 8 0
1pVL, plasma viral load.
2Patient numbers are shown.
doi:10.1371/journal.pone.0140791.t005
ART Adherence and CD4+ T Cell Count
PLOS ONE | DOI:10.1371/journal.pone.0140791 October 15, 2015 8 / 11
threshold of 100% that was found to be clinically significant in our study could in part be
explained by the high overall adherence level of our cohort, which could have resulted in a
decreased statistical power to detect significant effects at lower adherence levels. However, our
results are in line with a recent large study that examined relations between adherence and
virological suppression in 21,865 patients [24]. That study found a steady increase in propor-
tion of virologically suppressed patients with the increase in adherence up to 95% and higher,
and a distinction was made between patients treated with nonnucleoside reverse transcriptase
inhibitors (NNRTI) and protease inhibitors (PI): whereas adherence levels of>85% were for-
givable for the former, the latter had to demonstrate>95% adherence to achieve optimal viro-
logical suppression. Interestingly, in our study, a similar difference in the adherence-virological
suppression relationship was found between NNRTI- and PI-users (S1 Fig), although 100%
adherence was still associated with the highest levels of virological suppression in both strata.
Although CD4+ T cell count was not significantly associated with virological suppression, it
was found to strengthen the effects of suboptimal adherence on the virological suppression.
These effects were significant in patients with high CD4+ T cell counts but not in patients with
low or intermediate CD4+ T cell counts. It is possible that in patients with lower CD4+ counts,
other factors, such as increased immune activation [25], influence the residual virus produc-
tion/replication, masking the effects of suboptimal adherence on virological suppression,
whereas in patients with high CD4+ counts, these factors are insignificant or absent.
Our study has some limitations. One limitation is that it was focused on native Dutch
patients only. The observed effect of CD4+ count on adherence may be different among
patients of non-European descent treated in the Netherlands. In general, the results of this
study are applicable only to similar populations as described in this report. Another limitation
is that the patients included in this analysis had chosen to enroll in a behavioral intervention to
increase adherence, and while data for this study were collected before the intervention began,
it is still important to consider that patients may have made changes in their adherence to ther-
apy after inclusion. Another limitation relates to our adherence measurement method: as
MEMS only indicates if the bottle was open and not if the medication was actually taken, we
cannot exclude some slight overestimation of adherence due to “curiosity events”. A final limi-
tation is that our study was not designed to detect a behavioral mechanism that is mediating
the effect of high CD4+ count on adherence. Thus, our results warrant further studies to estab-
lish such underlying mechanisms.
In conclusion, in this cohort of 133 patients with relatively long time on ART, good immune
reconstitution, good virological suppression, and high overall electronically measured adher-
ence, high current CD4+ T cell count and twice-per-day dosing regimen significantly predicted
suboptimal adherence. It is possible that patients who are aware of their high CD4+ count
(interpreted as clinical success) may pay less attention to taking medications than patients with
lower CD4+ counts, as they feel that it is less crucial to maintain optimal adherence. However,
as we and others have shown that even modest nonadherence to ART may result in residual
virus replication [26,27], sustained efforts to emphasize continued adherence over time are
necessary, especially for patients with high CD4+ T cell counts.
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